Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.05 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 2 pathways; mostly protein handling | 0.90 |
No case: the score is under the bar. Receipt 4915
Sealed predictions
- SLC9A1 in dopamine neurons, braak-0.79 (p 0.012) → -0.17 (p 0.663)receipt 4920
Swarm cases
receipt 4920: SLC9A1 in dopamine neurons, braak
- power
- full sample -0.49 (p 0.037, n 18), 95% CI -0.78 to -0.04. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: -0.54 (p 0.021, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.49 (p 0.039, n 18). not the mix.
- skeptic
- leave-one-out range -0.65 to -0.43, sign flips 0; without severely affected donors -0.49 (p 0.037, n 18). robust.
- cell type
- strongest in microglia: -0.64 (p 0.0045, n 18) vs -0.49 in dopamine neurons. proposing microglia.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SLC9A1 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up SLC9A1 · microglia · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.57 p 0.041 (needs p < 4.0e-4)
Receipts
loading the receipts